** Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20
** Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA
** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting
** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo
** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously
** Also pushes submission seeking accelerated approval to late 2026 from H1 2026
** Stock down ~47% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。